Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) Stock Ticker

NASDAQ: IMDX · Healthcare · Medical - Diagnostics & Research
$3.92-0.76%
USD · as of 2026-09-27 · market cap $126.6M
Open IMDX in TickrDownload for iPhone

IMDX right now

Options price it to move more than 9 in 10 stocks.
Options expect by Oct 6±13.1%
Options expect by Oct 29±27.2%
Priced in for Nov 9 earnings±31.8%
IV rank (30-day)16% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full IMDX picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on IMDX
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Insight Molecular Diagnostics Inc.

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

IMDX stock facts

Ticker symbolIMDX
ExchangeNASDAQ Capital Market
SectorHealthcare
IndustryMedical - Diagnostics & Research
Market cap$126.6M
CEOJoshua Riggs
Employees57
HeadquartersNashville, TN, US
IPO date2015-12-30
Websiteimdxinc.com

What you can see for IMDX on Tickr

Live IMDX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the IMDX report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Insight Molecular Diagnostics Inc.?

The ticker symbol for Insight Molecular Diagnostics Inc. is IMDX, listed on the NASDAQ Capital Market.

What is IMDX?

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage…

HomeExploreMarketLists
All pages